▲ +36.25% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Ionis Pharmaceuticals in the last 3 months. The average price target is $68.18, with a high forecast of $91.00 and a low forecast of $49.00. The average price target represents a 36.25% upside from the last price of $50.04.
The current consensus among 13 polled investment analysts is to hold stock in Ionis Pharmaceuticals. This Hold consensus rating has held steady for over two years.
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic from ALS; ION859 for Parkinson's disease; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing severe and rare disease products, such as AKCEA-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-PKK-LRx for hereditary angioedema; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-ENAC-2.5Rx for cystic fibrosis; and ION357 for retinitis pigmentosa. In addition, its cardio metabolic and renal drugs include AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx for cardiovascular diseases; AKCEA-ANGPTL3-LRx for cardio metabolic disorders; IONIS-GCGRRx for type 2 diabetes; IONIS-AGT-LRX for the treatment of resistant hyper tension; IONIS-FXI-LRx for clotting disorders; IONIS-AZ4-2.5-LRx for cardiovascular diseases; and ION839 for nonalcoholic steatohepatitis. Further, the company develops products for oncology that include IONIS-AR-2.5Rx and danvatirsen for cancers; IONIS-HBVRx and IONIS-HBV-LRx for hepatitis B virus infection; and IONIS-FB-LRx for compliment meditated disease. It has a collaboration agreement with Genuity Science, Inc. for the discovery and development of various therapeutics across a range of approximately 20 diseases. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.